201 related articles for article (PubMed ID: 23222459)
1. Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy.
Wladis EJ; Falk NS; Iglesias BV; Beer PM; Gosselin EJ
Retina; 2013 Apr; 33(4):807-11. PubMed ID: 23222459
[TBL] [Abstract][Full Text] [Related]
2. The role of thrombin in proliferative vitreoretinopathy.
Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 2000 May; 129(5):678-80. PubMed ID: 10844070
[TBL] [Abstract][Full Text] [Related]
4. CONCENTRATIONS OF VITREAL CYTOKINES IN RHEGMATOGENOUS RETINAL DETACHMENT.
Danielescu C; Zugun-Eloae F; Zlei M
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):124-9. PubMed ID: 27125084
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 1999 Dec; 128(6):763-5. PubMed ID: 10612518
[TBL] [Abstract][Full Text] [Related]
6. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy.
Capeans C; De Rojas MV; Lojo S; Salorio MS
Retina; 1998; 18(6):546-50. PubMed ID: 9869464
[TBL] [Abstract][Full Text] [Related]
7. Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment.
Balogh A; Milibák T; Szabó V; Nagy ZZ; Kaarniranta K; Resch MD
BMC Ophthalmol; 2020 Dec; 20(1):491. PubMed ID: 33371882
[TBL] [Abstract][Full Text] [Related]
8. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
Roldán-Pallarés M; Rollín R; Mediero A; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
Mol Vis; 2005 Jul; 11():461-71. PubMed ID: 16030497
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression.
Zhang X; Barile G; Chang S; Hays A; Pachydaki S; Schiff W; Sparrow J
Curr Eye Res; 2005 May; 30(5):395-403. PubMed ID: 16020270
[TBL] [Abstract][Full Text] [Related]
10. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
Kon CH; Occleston NL; Aylward GW; Khaw PT
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
12. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
13. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders.
Banerjee S; Savant V; Scott RA; Curnow SJ; Wallace GR; Murray PI
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2203-7. PubMed ID: 17460280
[TBL] [Abstract][Full Text] [Related]
14. Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Ogata N; Nishikawa M; Nishimura T; Mitsuma Y; Matsumura M
Am J Ophthalmol; 2002 Jun; 133(6):851-2. PubMed ID: 12036691
[TBL] [Abstract][Full Text] [Related]
15. Levels of pentosidine in the vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment.
Tomé CC; De Rojas Silva MV; Rodríguez-García J; Rodríguez-Segade S; Sánchez-Salorio M
Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1272-6. PubMed ID: 15947940
[TBL] [Abstract][Full Text] [Related]
16. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
17. High-speed, high-resolution spectral optical coherence tomography in patients after vitrectomy with internal limiting membrane peeling for proliferative vitreoretinopathy retinal detachment.
Odrobina DC; Michalewska Z; Michalewski J; Nawrocki J
Retina; 2010 Jun; 30(6):881-6. PubMed ID: 20182404
[TBL] [Abstract][Full Text] [Related]
18. Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Wang ZY; Shen LJ; Zhao KK; Song ZM; Qu J
Ophthalmic Res; 2009; 42(3):138-40. PubMed ID: 19602911
[TBL] [Abstract][Full Text] [Related]
19. Active scatter factor (HGF/SF) in proliferative vitreoretinal disease.
Briggs MC; Grierson I; Hiscott P; Hunt JA
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3085-94. PubMed ID: 10967068
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation in human epiretinal membranes: characterization of cell types and correlation with disease condition and duration.
Oberstein SY; Byun J; Herrera D; Chapin EA; Fisher SK; Lewis GP
Mol Vis; 2011; 17():1794-805. PubMed ID: 21750605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
